Compound Evidence File
#EC-2026-0987
Enclomiphene
Filed under Oral Tablets. The bureau holds 175 laboratory returns for this compound from 58 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
58 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 10.0 | 10.0 | 21 May 2026 | 21 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 27 Dec 2025 | 5 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 10.0 | 10.0 | 12 Mar 2026 | 1 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Apr 2026 | 19 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Mar 2026 | 24 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 22 Apr 2026 | 21 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 25 Feb 2026 | 3 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Apr 2026 | 14 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 27 Jan 2026 | 3 Aug 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Feb 2026 | 19 Apr 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 10 May 2026 | 19 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 7 Dec 2025 | 21 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 10.0 | 10.0 | 10.0 | 13 May 2026 | 6 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 9 Dec 2025 | 27 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 10.0 | 10.0 | 10.0 | 22 Mar 2026 | 10 May 2026 |
| Orbitrex PeptidesCASE #VI-2026-0812 | X | 1 | 10.0 | 10.0 | 10.0 | 21 May 2025 | 21 May 2025 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Apr 2026 | 24 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Mar 2026 | 15 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 9.9 | 9.9 | 10.0 | 17 Feb 2026 | 11 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 9.9 | 9.9 | 10.0 | 16 Jan 2026 | 3 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 12 May 2026 | 18 May 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 9.9 | 3 Jul 2026 | 16 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 26 Feb 2026 | 1 May 2026 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 9.8 | 9.8 | 9.8 | 2 Apr 2025 | 2 Apr 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 9.2 | 7.8 | 10.0 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.9 | 7.8 | 9.6 | 23 May 2026 | 23 May 2026 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 1 | 8.8 | 8.8 | 8.8 | 8 Jul 2025 | 8 Jul 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.6 | 7.8 | 9.9 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.5 | 7.7 | 9.0 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.4 | 7.1 | 9.8 | 23 May 2026 | 23 May 2026 |
| Planet PeptideCASE #VI-2026-0092 | X | 5 | 7.5 | 5.9 | 9.4 | 3 Jun 2025 | 23 May 2026 |
| HK PeptidesCASE #VI-2026-0140 | X | 12 | 6.9 | 4.6 | 10.0 | 24 Apr 2025 | 24 May 2026 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 6.9 | 6.9 | 6.9 | 9 Jun 2025 | 9 Jun 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 15 | 6.8 | 4.6 | 8.9 | 21 May 2025 | 21 May 2026 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 6.7 | 6.7 | 6.7 | 17 Dec 2024 | 17 Dec 2024 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 6.7 | 6.7 | 6.7 | 25 Apr 2025 | 25 Apr 2025 |
| Peptide CraftersCASE #VI-2026-0994 | X | 3 | 6.6 | 5.3 | 8.0 | 8 Jul 2025 | 21 May 2026 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 6.6 | 6.6 | 6.6 | 13 Jun 2025 | 13 Jun 2025 |
| Pure RawzCASE #VI-2026-0767 | X | 2 | 6.5 | 5.9 | 7.0 | 27 Feb 2025 | 25 May 2026 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 6.5 | 6.5 | 6.5 | 21 May 2025 | 21 May 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 6.4 | 6.4 | 6.4 | 14 Jan 2025 | 14 Jan 2025 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 6.3 | 6.3 | 6.3 | 16 Mar 2025 | 16 Mar 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 6.2 | 6.2 | 6.2 | 11 Jun 2025 | 11 Jun 2025 |
| Peptide SciencesCASE #VI-2026-0867 | X | 11 | 6.1 | 3.7 | 8.3 | 13 Feb 2025 | 23 May 2026 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 4 | 6.1 | 5.4 | 7.0 | 21 May 2025 | 24 May 2026 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 6.1 | 6.1 | 6.1 | 27 Feb 2025 | 27 Feb 2025 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 6.1 | 6.1 | 6.1 | 27 Feb 2025 | 27 Feb 2025 |
| Shaanxi Dideu MedichemCASE #VI-2026-0499 | X | 1 | 5.7 | 5.7 | 5.7 | 20 Jun 2025 | 20 Jun 2025 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 5.1 | 5.1 | 5.1 | 3 Jul 2025 | 3 Jul 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 4.2 | 4.2 | 4.2 | 7 May 2025 | 7 May 2025 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 3.9 | 3.9 | 3.9 | 17 Dec 2024 | 17 Dec 2024 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 3.7 | 3.7 | 3.7 | 2 Apr 2025 | 2 Apr 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 2.8 | 2.8 | 2.8 | 3 Jun 2025 | 3 Jun 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 2.6 | 2.6 | 2.6 | 8 Jul 2025 | 8 Jul 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 1.6 | 1.6 | 1.6 | 14 Jan 2025 | 14 Jan 2025 |
| Lejian Biotech PeptideCASE #VI-2026-0746 | X | 1 | 0.0 | 0.0 | 0.0 | 9 Jun 2025 | 9 Jun 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Apr 2025 | 2 Apr 2025 |
Open any subject to view the batch-level evidence for Enclomiphene alone.